↓ Skip to main content

Primaquine for preventing relapse in people withPlasmodium vivaxmalaria treated with chloroquine

Overview of attention for article published in Cochrane database of systematic reviews, October 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

policy
1 policy source
twitter
5 tweeters

Citations

dimensions_citation
64 Dimensions

Readers on

mendeley
280 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Primaquine for preventing relapse in people withPlasmodium vivaxmalaria treated with chloroquine
Published in
Cochrane database of systematic reviews, October 2013
DOI 10.1002/14651858.cd004389.pub3
Pubmed ID
Authors

Gawrie NL Galappaththy, Prathap Tharyan, Richard Kirubakaran

Abstract

Plasmodium vivax infections are an important contributor to the malaria burden worldwide. The World Health Organization recommends a 14-day course of primaquine (0.25 mg/kg/day, giving an adult dose of 15 mg/day) to eradicate the liver stage of the parasite and prevent relapse of the disease. Many people find a 14-day primaquine regimen difficult to complete, and there is a potential risk of haemolytic anaemia in people with glucose-6-phosphate-dehydrogenase enzyme (G6PD) deficiency. This review evaluates primaquine in P. vivax, particularly alternatives to the standard 14-day course.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 280 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 <1%
Italy 1 <1%
Brazil 1 <1%
United Kingdom 1 <1%
Japan 1 <1%
Unknown 275 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 46 16%
Researcher 32 11%
Student > Ph. D. Student 29 10%
Student > Bachelor 29 10%
Student > Postgraduate 16 6%
Other 62 22%
Unknown 66 24%
Readers by discipline Count As %
Medicine and Dentistry 94 34%
Nursing and Health Professions 26 9%
Agricultural and Biological Sciences 18 6%
Social Sciences 16 6%
Biochemistry, Genetics and Molecular Biology 12 4%
Other 39 14%
Unknown 75 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2022.
All research outputs
#4,696,560
of 22,788,370 outputs
Outputs from Cochrane database of systematic reviews
#7,064
of 12,314 outputs
Outputs of similar age
#44,258
of 212,277 outputs
Outputs of similar age from Cochrane database of systematic reviews
#133
of 215 outputs
Altmetric has tracked 22,788,370 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,314 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.4. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,277 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 215 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.